Sills M A, Jacobowitz D M
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892.
Peptides. 1988 Jul-Aug;9(4):893-8. doi: 10.1016/0196-9781(88)90138-6.
Thyrotropin-releasing hormone (TRH) has been shown to increase heart rate as well as blood pressure when administered into rat brain. The present study investigated the mechanism by which the TRH analog MK-771 produces these effects when injected into the preoptic suprachiasmatic nucleus (POSC). MK-771, at a dose of 125 pmol (50 ng), produced significant increases in both heart rate and blood pressure. These effects occurred within 5 minutes of microinjection and lasted approximately 20-30 minutes. Pretreatment with either the beta-adrenergic antagonist propranolol or the muscarinic antagonist methylatropine, administered into the POSC, significantly altered the response produced by MK-771. Propranolol, at a dose of 7 nmol, and methylatropine at a dose of 0.5 nmol, significantly inhibited the tachycardia produced by MK-771. In addition, methylatropine, at a dose of 0.5 nmol, significantly reduced the increase in diastolic pressure produced by the TRH agonist. These results are consistent with the idea that TRH agonists, when administered centrally, produce cardiovascular alterations through the autonomic nervous system.
促甲状腺激素释放激素(TRH)已被证明,当注入大鼠脑内时会增加心率和血压。本研究调查了TRH类似物MK-771注入视前交叉上核(POSC)时产生这些效应的机制。剂量为125皮摩尔(50纳克)的MK-771显著增加了心率和血压。这些效应在微量注射后5分钟内出现,持续约20 - 30分钟。预先向POSC注射β-肾上腺素能拮抗剂普萘洛尔或毒蕈碱拮抗剂甲基阿托品,会显著改变MK-771产生的反应。剂量为7纳摩尔的普萘洛尔和剂量为0.5纳摩尔的甲基阿托品显著抑制了MK-771产生的心动过速。此外,剂量为0.5纳摩尔的甲基阿托品显著降低了TRH激动剂引起的舒张压升高。这些结果与以下观点一致:TRH激动剂在中枢给药时,通过自主神经系统产生心血管改变。